SARS-2 variantti BA.3.2 ilmenee. VUM. Tällä omicron BA.3 johdannaisella on evaasiokapasiteettia rokotetuissa.. ehkä

 https://data.who.int/dashboards/covid19/variants?n=c

Genetic features
Relative to Index: P9L, R21T, P26L, A67V, H69-, V70-, T95I, I101T, C136-, N137-, D138-, P139-, F140-, L141-, G142-, V143-, Y144-, Y145-, H146-, K147-, F157S, N164K, S172F, K187T, N211-, L212I, A243-, L244-, P251S, I326V, G339Y, A348P, S371F, S373P, S375F, R403K, D405N, R408S, K417N, A435S, N440R, V445A, G446D, L452W, N460K, S477N, T478N, E484K, G496S, Q498R, N501Y , K529N, E554D, E583D, D614G, H625R, N641K, V642G, E654K, H655Y , N679R, P681R, A688D, S704L, N764K, K795T, D796Y , A852K, S939F, Q954H, N969K, P1162R, D1184E

Earliest documented samples
22 November 2025

Date of designation
5 December 2025

Risk assessment
• 05 December 2025
  BA.3.2 Initial Risk Evaluation
• WHO TAG-VE Risk Evaluation for SARS-CoV-2 Variant Under Monitoring: BA.3.2 Executive Summary BA.3.2 has been designated a SARS-CoV-2 Variant Under Monitoring (VUM). Although it demonstrates antigenic drift and reduced neutralization in vitro, currently approved COVID-19 vaccines are expected to continue providing protection against severe disease. There have been reports from Western Australia of elevated BA.3.2 wastewater signals. Recently, BA.3.2 was detected, though still very low-level, in wastewater from some U.S. states. However, BA.3.2 has not shown a sustained growth advantage over any other cocirculating variant, and no data indicate increased severity, hospitalisations, or deaths associated with this variant. Overall, available evidence suggests that BA.3.2 poses low additional public health risk compared with other circulating Omicron descendent lineages.
• Initial Risk Evaluation of BA.3.2, 5 December 2025 BA.3.2 is a SARS-CoV-2 variant that is a descendent lineage of the Omicron variant BA.3, Figure 1A, differing from BA.3 in the Spike protein by 53 mutations [1], Figure 1B, with the earliest sample collected on 22 November 2024. Phylodynamic analysis estimates the variant to have emerged between December 2023 and July 2024 [2]. BA.3.2 is one of six VUMs tracked by the WHO [3,4]

PubMed haku OMICRON BA.3.2 
2 artikkelia:

1

 

Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG and BA.3.2 following KP.2 monovalent mRNA vaccination.

Abbad A, Lerman B, Ehrenhaus J, Monahan B, Singh G, Wilson A, Slamanig S, Aracena A, Lyttle N, Nardulli J, Farrugia K, Khalil Z, Gonzalez-Reiche AS, Sordillo EM, Sun W, van Bakel HM, Simon V, Krammer F.medRxiv [Preprint]. 2025 Sep 19:2025.08.24.25333689. doi: 10.1101/2025.08.24.25333689.Update in: mBio. 2026 Jan 14;17(1):e0290125. doi: 10.1128/mbio.02901-25.PMID: 40909860 Free PMC article. Preprint.

We assessed neutralizing antibody responses in 56 adults with varied exposure histories following KP.2 vaccination against emerging variants including LP.8.1, LF.7.1, NB.1.8.1, XFG, and BA.3.2. While KP.2 vaccination enhanced neutralization against homologous …

2

 

Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG, and BA.3.2 following KP.2 monovalent mRNA vaccination.

Abbad A, Lerman B, Ehrenhaus J, Monahan B, Singh G, Wilson A, Slamanig S, Aracena A, Lyttle N, Nardulli JR, Farrugia K, Khalil Z, Gonzalez-Reiche AS, Sordillo ME, Sun W, van Bakel H, Simon V, Krammer F.mBio. 2026 Jan 14;17(1):e0290125. doi: 10.1128/mbio.02901-25. Epub 2025 Nov 25.PMID: 41288098 Free PMC article.

We assessed neutralizing antibody responses in 56 adults with varied exposure histories following KP.2 vaccination against emerging variants including LP.8.1, LF.7.1, NB.1.8.1, XFG, and BA.3.2. While KP.2 vaccination enhanced neutralization against homologous …

Volume 6, Issue 11101165November 2025Open access

Host cell entry and neutralisation sensitivity of SARS-CoV-2 BA.3.2

Lu Zhanga ∙ Amy Kempfa,b ∙ Inga Nehlmeiera ∙ Nianzhen Chena ∙ Metodi V Stankovd,f ∙ Christine Happlec,d,e,f ∙ et al. Show more

WHO päivitysyhteenveto Covid-19 Sars-Cov-2 viruksesta

 https://data.who.int/dashboards/covid19/summary?n=o    Kummallista , että BA.3 linja antaa nyt jonkin variantin. Katson sitä erikseen.  

The objective of this report is to provide a comprehensive overview of reported data on SARS-CoV-2 viral activity and the burden of the COVID-19 on the human population over the past seven to 28 days from the last reporting date. This overview and other sections are based on data submitted by Member States' Ministries of Health to the World Health Organization (WHO) through various surveillance systems, as well as updates from the health ministries' websites of the Member States. Information in this overview should be interpreted considering the data limitations detailed beneath each section.

Circulation

SARS-CoV-2 activity: Last 7 days

In the week of 29 December 2025 to 4 January 2026, a total of 75,393 samples were tested for SARS-CoV-2, the virus that causes COVID-19, across 66 countries (Table 1.1, 1.2). WHO collects this data from a global network of sentinel and systematic virologic surveillance sites. Out of these, 3,363 (4.5%) samples tested positive for the virus. During this period, SARS-CoV-2 activity was low and stable globally, with variations observed across some WHO regions. Elevated activity or increases were reported in countries in Temperate South America, Northern and Eastern Europe, and South-East and Eastern Asia.

n the 28-day period from 08 December 2025 to 04 January 2026, 65 countries across three WHO regions reported new COVID-19 cases. During this 28-day period, a total of 49,665 new cases were reported, which is a decrease compared to the 71,224 new cases reported from 88 countries in the previous 28-day period (Table 2.1, 2.2). Overall, 12 countries from the Americas and Europe showed an increase in new cases of over 10%.

SARS-CoV-2 variant circulation: 30 November to 28 December 2025

WHO is currently tracking several SARS-CoV-2 variants:

• Variants of Interest: JN.1
• Variants Under Monitoring: XFG, NB.1.8.1, KP.3.1.1, BA.3.2, and LP.8.1

At the global level, the most prevalent variant, XFG, accounted for 75% of all submitted sequences in the week ending on 28 December 2025 which is an increase from 68% in the week ending on 30 November 2025. Within the same reporting period, NB.1.8.1 accounted for 9% of all submitted sequences, a decrease from 15%, and BA.3.2 remained stable, accounting for 3% of all submitted sequences (Table 3).

During this reporting period, all other variants showed a decreasing or stable trend. Available evidence suggests that XFG, NB.1.8.1, and BA.3.2 do not pose additional public health risks relative to other currently circulating SARS-CoV-2 variants.

At the regional level, within the reporting period from week ending 30 November to 28 December 2025, XFG increased in the Western Pacific Region and remained stable in the European Region and in the Americas, which were the regions with sufficient data. NB.1.8.1 increased in the European Region and remained stable in the Americas, and BA.3.2 increased in the European Region.

Deaths: Last 28 days

In the 28-day period from 08 December 2025 to 04 January 2026, 39 countries across three WHO regions reported new COVID-19 deaths. During this 28-day period, a total of 1,286 new deaths were reported (Table 5.1), which is an increase compared to the 1,044 new deaths reported from 39 countries in the previous 28-day period (Table 5.2). Thirteen countries from the Americas and Europe showed an increase in new deaths of over 10%. In December 2025, 91% of reported deaths with age information occurred in the population aged 65 and over.